{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:37:03Z","timestamp":1790109423237,"version":"4.0.1"},"reference-count":37,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: In recent years, there have been significant advances in the understanding and treatment of multiple myeloma (MM). Despite this progress, there is still limited information on the disease in patients aged 50 or younger, including the impact of young age on disease characteristics, treatment, and outcome. Methods: In this retrospective study, we analyzed 68 newly diagnosed MM patients aged \u2264 50 years (y) who had undergone at least one peripheral blood stem cell transplantation (PBSCT). Additionally, we reviewed data published during 2008\u20132022 and compared these to our cohort. Results: Of note, the disease characteristics in our cohort were similar to those in older patients. However, the incidence of bone lesions was higher in younger patients (84%). Moreover, 33% had LC-only MM and 7% had high-risk (del17p, t(14;16), t(4;14)) cytogenetics. Advanced ISS and R-ISS II\/III were observed in 57% and 78%, respectively. Therapy was intense, with 53% of patients undergoing \u22652 SCTs. Median follow-up was 75 months, median progression-free survival was 57 months, and median overall survival (OS) was not reached. The 10-year OS rate was 72%, with only 19% succumbing to the disease. Notably, no specific therapeutic regimen or risk factors for worse outcomes were identified through uni- or bivariate analyses, even in subgroup analyses of younger patients aged \u2264 40 y. Conclusions: Our, and prior, results of young (&lt;50 y) and very young (&lt;40 y) MM patients underscore the need for further comprehensive studies focused on this significantly affected cohort.<\/jats:p>","DOI":"10.3390\/cancers16234090","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T06:25:16Z","timestamp":1733466316000},"page":"4090","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Characteristics, Cytogenetic Risks, and Prognoses of Young Multiple Myeloma Patients in the Era of Novel Therapies"],"prefix":"10.3390","volume":"16","author":[{"given":"Nathalie","family":"Borst","sequence":"first","affiliation":[{"name":"The Department of Hematology, Oncology, and Stem-Cell Transplantation, Faculty of Medicine and Medical Center, University of Freiburg, 79106 Freiburg im Breisgau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-1589","authenticated-orcid":false,"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg im Breisgau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Wenger","sequence":"additional","affiliation":[{"name":"The Department of Hematology, Oncology, and Stem-Cell Transplantation, Faculty of Medicine and Medical Center, University of Freiburg, 79106 Freiburg im Breisgau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"R\u00e4der","sequence":"additional","affiliation":[{"name":"The Department of Hematology, Oncology, and Stem-Cell Transplantation, Faculty of Medicine and Medical Center, University of Freiburg, 79106 Freiburg im Breisgau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-3444","authenticated-orcid":false,"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[{"name":"The Department of Hematology, Oncology, and Stem-Cell Transplantation, Faculty of Medicine and Medical Center, University of Freiburg, 79106 Freiburg im Breisgau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"The Department of Hematology, Oncology, and Stem-Cell Transplantation, Faculty of Medicine and Medical Center, University of Freiburg, 79106 Freiburg im Breisgau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-9511","authenticated-orcid":false,"given":"Michael","family":"Rassner","sequence":"additional","affiliation":[{"name":"The Department of Hematology, Oncology, and Stem-Cell Transplantation, Faculty of Medicine and Medical Center, University of Freiburg, 79106 Freiburg im Breisgau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple Myeloma Epidemiology and Survival, a Unique Malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood.2021011285","article-title":"Epidemiological Landscape of Young Patients with Multiple Myeloma Diagnosed before 40 Years of Age: The French Experience","volume":"138","author":"Caulier","year":"2021","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.htct.2020.06.014","article-title":"Young Age and Autologous Stem Cell Transplantation Are Associated with Improved Survival in Newly Diagnosed Multiple Myeloma","volume":"43","author":"Bove","year":"2021","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/10428194.2018.1480766","article-title":"Multiple Myeloma in Patients up to 30 Years of Age: A Multicenter Retrospective Study of 52 Cases","volume":"60","author":"Jurczyszyn","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clml.2016.11.006","article-title":"Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age","volume":"17","author":"Dhakal","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bjh.14328","article-title":"Characteristics and Outcomes of Patients with Multiple Myeloma Aged 21\u201340 Years versus 41\u201360 Years: A Multi-Institutional Case-Control Study","volume":"175","author":"Jurczyszyn","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","article-title":"Myeloma in Patients Younger than Age 50 Years Presents with More Favorable Features and Shows Better Survival: An Analysis of 10,549 Patients from the International Myeloma Working Group","volume":"111","author":"Ludwig","year":"2008","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.bbmt.2009.02.013","article-title":"Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant","volume":"15","author":"Cheema","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3904\/kjim.2016.256","article-title":"Clinicopathological Characteristics of Extremely Young Korean Multiple Myeloma Patients: Therapeutic Implications","volume":"32","author":"Shin","year":"2017","journal-title":"Korean J. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/JBM.S380133","article-title":"Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??","volume":"13","author":"Kaloyannidis","year":"2022","journal-title":"J. Blood Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1056\/NEJMe2314067","article-title":"Antibody-Based Therapy for Transplantation-Eligible Patients with Multiple Myeloma","volume":"390","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_13","first-page":"318","article-title":"In-Depth Cytogenetic and Immunohistochemical Analysis in a Real World Cohort\u2014Reconsidering the Role of Primary and Secondary Aberrations in Multiple Myeloma","volume":"109","author":"Wenger","year":"2024","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/10428194.2019.1695051","article-title":"Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma (MM)\u2014Possible Risks and Future Solutions: Retrospective and Prospective \u2018Deutsche Studiengruppe MM\u2019 (DSMM) and \u2018European Myeloma Network\u2019 (EMN) Analysis","volume":"61","author":"Graziani","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric Assessment in Multiple Myeloma Patients: Validation of the International Myeloma Working Group (IMWG) Score and Comparison with Other Common Comorbidity Scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Greil, C., Engelhardt, M., Finke, J., and W\u00e4sch, R. (2021). Allogeneic Stem Cell Transplantation in Multiple Myeloma. Cancers, 14.","DOI":"10.3390\/cancers14010055"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41375-019-0537-2","article-title":"Allogeneic Transplantation in Multiple Myeloma: Long-Term Follow-up and Cytogenetic Subgroup Analysis","volume":"33","author":"Knop","year":"2019","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12253-018-0526-1","article-title":"Multiple Myeloma of the Young\u2014A Single Center Experience Highlights Future Directions","volume":"26","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000507414","article-title":"Multiple Myeloma Presenting in Patients Younger than 50 Years of Age: A Single Institution Experience","volume":"144","author":"Duek","year":"2021","journal-title":"Acta Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","article-title":"Immunosenescence: A Key Player in Cancer Development","volume":"13","author":"Lian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","article-title":"Cancer Immunoediting and Immune Dysregulation in Multiple Myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","article-title":"Survival and Years of Life Lost in Different Age Cohorts of Patients with Multiple Myeloma","volume":"28","author":"Ludwig","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3324\/haematol.2016.145078","article-title":"Evaluation of the Revised International Staging System in an Independent Cohort of Unselected Patients with Multiple Myeloma","volume":"102","author":"Kastritis","year":"2017","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current Status of Autologous Stem Cell Transplantation for Multiple Myeloma","volume":"9","author":"Bazarbachi","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1016\/S2352-3026(20)30323-9","article-title":"Bortezomib, Thalidomide, and Dexamethasone Followed by Double Autologous Haematopoietic Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (GIMEMA-MMY-3006): Long-Term Follow-up Analysis of a Randomised Phase 3, Open-Label Study","volume":"7","author":"Tacchetti","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, Randomized Study of Single Compared with Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study","volume":"25","author":"Cavo","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous Haematopoietic Stem-Cell Transplantation versus Bortezomib\u2013Melphalan\u2013Prednisone, with or without Bortezomib\u2013Lenalidomide\u2013Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (EMN02\/HO95): A Multicentre, Randomised, Open-Label, Phase 3 Study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem Autologous\/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation versus Autologous Transplantation in Myeloma: Long-Term Follow-Up","volume":"29","author":"Iacobelli","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/Reduced-Intensity Allogeneic Stem Cell Transplantation vs Autologous Transplantation in Multiple Myeloma: Long-Term Results of the EBMT-NMAM2000 Study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1182\/blood-2011-03-339945","article-title":"Long-Term Follow-up of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma","volume":"117","author":"Giaccone","year":"2011","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and\/or Refractory Multiple Myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"ref_34","first-page":"1469","article-title":"Autologous-Allogeneic versus Autologous Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide for Multiple Myeloma Patients Less than 60 Years of Age: A Prospective Phase II Study","volume":"109","author":"Wulf","year":"2020","journal-title":"Haematologica"},{"key":"ref_35","first-page":"e2300182","article-title":"Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients\u2019 Evidence From Latin America","volume":"9","author":"Schutz","year":"2023","journal-title":"JCO Glob. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.3390\/curroncol30060396","article-title":"Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes","volume":"30","author":"Tanguay","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clml.2023.08.019","article-title":"Multiple Myeloma in Young Patients: A Scoping Review","volume":"24","author":"Steinbach","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/23\/4090\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:48:31Z","timestamp":1760114911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/23\/4090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":37,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16234090"],"URL":"https:\/\/doi.org\/10.3390\/cancers16234090","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]}}}